Previous 10 | Next 10 |
home / stock / onc:cc / onc:cc news
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort PR Newswire One complete response (CR) and eight partial responses (PR) achie...
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and research is constantly advancing. Pancreatic cancer is 12 ...
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights PR Newswire Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average...
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting PR Newswire 70% objective response rate ( ORR ; n=10) is nearly triple the average ORR of ~25% rep...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights PR Newswire Conference call and webcast to take place on Monday, November 7, 2022 , at 8:30 a.m. ET SAN DIEGO, Calif. and ...
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatmen...
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors Canada NewsWire Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEG...
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights Canada NewsWire Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational st...
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Canada NewsWire Conference call and webcast to take place on Thursday, August 11, 2022 , at 8:30 a.m. ET SAN DIEGO, CA and...
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and inc...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...